Prolonged Aldose Reductase Inhibition in Chronic Peripheral Diabetic Neuropathy: Effects on Microangiopathy

• DOI: 10.1111/j.1464-5491.1990.tb01310.x
• Publication Date: 2009-07-30T10:23:26Z
• Authors: P.E. Jennings; S. Nightingale; C. Le Guen; N. Lawson; J.R. Williamson; P. Hoffman; A.H. Barnett
• Keywords: Microangiopathy; Diabetic Neuropathy

A 2‐year randomized placebo‐controlled double‐blind trial of 250 mg day −1 the aldose reductase inhibitor Sorbinil in severe symptomatic chronic peripheral neuropathy was performed 21 diabetic patients. Due to adverse reactions 8 patients completed on and 6 placebo. Despite differences baseline neurophysiological parameters, duration diabetes, presence retinopathy between placebo treatment groups, there were no initial vitro platelet aggregation, albumin excretion rate (AER) or muscle capillary basement membrane thickness. After 2 years median deterioration AER group 18.4 μg min (range 2.6–64.8 ). This significant ( p < 0.03). The change +1.25 (‐10.7 +20.4) , an insignificant change. In responsiveness collagen adenosine diphosphate (ADP) increased (median max% + (+2 +30)%; ADP +4.5 (0 +20)% compared with a fall treated change; −17.5 (‐2 −40)%, 0.05; ADP, −4 −25)%, 0.05). Muscle thickness measured only 3 each did not alter significantly during trial. All 12 measurements showed changes groups. data suggest that inhibition has effects reactivity microalbuminuria.